Reacting to this, shares of the company opened the day on a weak note and lost further to 15.6 percent to Rs 799.05 at BSE. As a part of the integration process with Ranbaxy, the company expects to incur certain integration charges in order to generate long-term synergies from this merger, Sun Pharma said in a statement yesterday.

Also, the company may look to discontinue certain non-strategic businesses, it said. As per the company's estimates, the consolidated revenues would remain flat or show a decline over FY15. Also, the consolidated profits may also be adversely impacted due to certain expenses/charges arising out of integration as well as remedial actions.

For the year ended March 31, the company posted a net profit of Rs 4,540.60 crore, while the same stood at Rs 3,141.47 crore in the previous year. The company had completed the USD 4 billion merger deal with Ranbaxy Laboratories in March this year.

Read more: Japan's Daiichi Sankyo completely exits Sun Pharma

Read more: Sun Pharma to delist Ranbaxy on completion of USD4 billion merger

Latest News  from Business News Desk